Are German Health Insurers Obliged to Purchase Drugs by Public Tender?

Just three months ago, reforms to the German healthcare system came into effect bringing profound changes to the market for pharmaceuticals. Cost-benefit analyses and compulsory second opinions have been introduced into the prescribing process, and payers and care providers now have more power to negotiate. Bettina Tugendreich and Maren Bedau examine companies' legal rights in the face of the reforms.


Download PDF Back To Listing
Loading data